Bill Bowes

In Memoriam (1926 - 2016)

Print Page

William K. Bowes, Jr., known affectionately by everyone as just “Bill” was not only the founder of U. S. Venture Partners (“USVP”), he was one of the true pioneers of Silicon Valley and venture capital. Bill passed away peacefully in his home with his loving wife of more than 50 years, Ute, on Wednesday evening December 28th.

A venture capitalist in the Bay Area for nearly 50 years, Bill founded and helped to build USVP to what it is today. His belief that venture capitalists should guide companies based on real-world experience continues to set the tone at USVP.

Bill was the founding shareholder of Amgen and was its first Chairman and Treasurer. Prior to founding USVP, he'd already had success as a venture capitalist with companies like Cetus, Raychem (where he served on the board from 1961 until the late 1970s), and Dymo Industries. Bill had previously been Senior Vice President and Director of Blyth Eastman Dillon & Company, where he worked from 1953 to 1978 and was a consultant to Blyth Eastman Paine Webber from 1978 to 1980.

At USVP, Bill led the firm's investments in Advanced Cardiovascular Systems, Applied Biosystems, Devices for Vascular Intervention, Glycomed, Sun Microsystems and Ventritex.

Bill devoted much of his time to education and medical research. He was on the executive committee of the San Francisco Conservatory of Music and also as Board Chairman of The Exploratorium, San Francisco's exemplary interactive museum of the sciences. He also served on the Board of the Asian Art Museum, Grace Cathedral and the Hoover Institution.

Having focused his investment career largely in the medical industry, Bill remained involved through some of his nonprofit work. He was on the Board of Directors of the UCSF Foundation and was Chairman of the Mission Bay Capital Campaign. He served on the Advisory Committees of Bio-X, the Institute for Systems Biology, QB3 and Harvard Partners Center for Genetics and Genomics - each dedicated to furthering interdisciplinary medical research. He was on the visiting committee at the Harvard Business School.

More